Background
Methods
Patients
Evaluation of the humoral immune response
Evaluation of blood-CSF barrier function
Cytological examination, total CSF protein and l-lactate
Statistics
Results
Epidemiology and autoantibody status
Units | Pattern I MS | Patterns II + III MS | Pattern II MS | Pattern III MS | AQP4-Ab+ NMO [48] | |
---|---|---|---|---|---|---|
Patients |
N
| 10 | 23 | 16 | 7 | 89 |
Samples |
N
| 19 | 49 | 30 | 19 | 211 |
Age at first LP | Years | 30 (13–47) | 36 (20–63) | 35 (20–51) | 38 (26–63) | 39.5 (14–79) |
Sex ratio | m:f | 1:1 | 1:2.3 | 1:2.2 | 1:2.5 | 1:12.1 |
Oligoclonal bands
Units | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | AQP4-IgG+ NMO [48] | MOG-IgG+ EM [35] | |
---|---|---|---|---|---|---|---|
CSF-restricted OCB | Samples | 15/17 (88.2) | 10/37 (27) | 9/25 (36) | 1/12 (8.3) | 29/177 (16.4) | 8/47 (17) |
CSF-restricted OCB | Patients | 8/10 (80) | 7/22 (31.8) | 6/16 (37.5) | 1/6 (16.7) | 22/80 (27.5) | 6/45 (13) |
CSF-restricted OCB, without transient OCB | Patients | 8/10 (80) | 5/22 (22.7) | 5/16 (31.3) | 0/6 (0) | 16/80 (20) | 6/45 (13) |
OCB, IEF pattern 1 | Samples | 2/15 (13.3) | 24/35 (68.6) | 13/23 (56.5) | 11/12 (91.7) | 127/177 (71.8) | n.d. |
OCB, IEF pattern 2 | Samples | 13/15 (86.7) | 7/35 (20) | 6/23 (26.1) | 1/12 (8.3) | 19/177 (10.7) | n.d. |
OCB, IEF pattern 3 | Samples | 0/15 (0) | 1/35 (2.9) | 1/23 (4.3) | 0/12 (0) | 10/177 (5.6) | n.d. |
OCB, IEF pattern 4 | Samples | 0/15 (0) | 1/35 (2.9) | 1/23 (4.3) | 0/12 (0) | 20/177 (11.3) | n.d. |
OCB, IEF pattern 5 | Samples | 0/15 (0) | 3/35 (8.6) | 2/23 (8.7) | 1/12 (8.3) | 1/177 (0.6) | n.d. |
QIgG > Qlim(IgG) | Patients | 3/10 (30) | 4/21 (19) | 4/14 (28.6) | 0/7 (0) | n.d. | n.d. |
QIgG > Qlim(IgG) | Samples | 7/17 (41.2) | 5/41 (12.2) | 5/24 (20.8) | 0/17 (0) | 13/143 (9) | n.d. |
QIgG, all LPs | – | 3.6 (1.9–9.35; 17) | 4.75 (1.3–21.5; 42) | 4.8 (1.3–21.5; 25) | 4.7 (1.98–12.6; 17) | 3.9 (0.2–58.1; 135) | n.d. |
QIgG, if positive | – | 3.63 (2.6–9.35; 7) | 5.03 (3.2–8.8; 5) | 5.03 (3.2–8.8; 5) | n.a. | 5.7 (2.5–58.1; 12) | n.d. |
IgGloc, all LPs | mg/L | 0 (0–75.76; 17) | 0 (0–51.17; 41) | 0 (0–51.17; 24) | 0 (0–0; 17) | 0 (0–441.4; 135) | n.d. |
IgGloc, QIgG positives | mg/L | 5.91 (2.31–75.76; 7) | 16.75 (11.79–51.17; 5) | 16.75 (11.79–51.17; 5) | n.a. | 13.9 (1.3–441.4; 12) | n.d. |
IgGIF, all LPs | % | 0 (0–0.58; 17) | 0 (0–0.59; 41) | 0 (0–0.59; 24) | 0 (0–0; 17) | 0 (0–90.6; 135) | n.d. |
IgGIF, QIgG positives | % | 0.14 (0.06–0.58; 7) | 0.47 (0.22–0.59; 5) | 0.47 (0.22–0.59; 5) | n.a. | 32.5 (2.8–90.6; 12) | n.d. |
IgG CSF, all LPs | mg/L | 39.9 (11–130; 17) | 43.7 (11.4–146; 41) | 46 (11.4–109; 24) | 37.7 (21–146; 17) | 37.9 (2.4–487; 136) | n.d. |
IgG CSF, QIgG positives | mg/L | 39.9 (16.8–130; 7) | 53.3 (22.9–109; 5) | 53.3 (22.9–109; 5) | n.a. | 70.6 (20.5–487; 12) | n.d. |
IgG serum, all LPs | g/L | 10 (3.9–28.04; 17) | 8.75 (5.55–28.9; 41) | 10.39 (5.55–24.8; 24) | 7.5 (6.15–28.9; 17) | 10 (1.9–55.8; 134) | n.d. |
IgG serum, QIgG positives | g/L | 9.21 (3.9–15.3; 7) | 8.75 (7.1–12.4; 5) | 8.75 (7.1–12.4; 5) | n.a. | 10.7 (2.4–18; 12) | n.d. |
IgG, IgM and IgA CSF/serum ratios
Units | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | AQP4-IgG+ NMO [48] | |
---|---|---|---|---|---|---|
QIgM > Qlim(IgM) | Patients | 3/9 (33.3) | 3/17 (17.6) | 3/12 (25) | 0/5 (0) | n.d. |
QIgM > Qlim(IgM), LPs | Samples | 3/16 (18.8) | 5/30 (16.7) | 5/20 (25) | 0/10 (0) | 13/96 (14%) |
QIgM, all LPs | – | 0.58 (0.26–1.5; 15) | 0.65 (0.1–14.1; 26) | 0.8 (0.1–14.1; 17) | 0.6 (0.5–5.8; 9) | 0.9 (0–40.5; 97) |
QIgM, if positive | – | 0.8 (0.58–1.5; 3) | 9.8 (3.5–14.1; 5) | 9.8 (3.5–14.1; 5) | n.a. | 8.3 (1.2–40.5; 13) |
IgMloc, all LPs | mg/L | 0 (0–0.27; 16) | 0 (0–9.24; 29) | 0 (0–9.24; 19) | 0 (0–0; 10) | 0 (0–35.3; 95) |
IgMloc, QIgM positives | mg/L | 0.12 (0.05–0.27; 3) | 6.41 (0.86–9.24; 5) | 6.41 (0.86–9.24; 5) | n.a. | 0.9 (0–35.3; 13) |
IgMIF, all LPs | % | 0 (0–0.12; 16) | 0 (0–0.86; 30) | 0 (0–0.86; 20) | 0 (0–0; 10) | 0 (0-95.8; 95) |
IgMIF, QIgM positives | % | 0.1 (0.09-0.12; 3) | 0.71 (0.17–0.86; 5) | 0.71 (0.17–0.86; 5) | n.a. | 15.3 (2.3–95.8; 13) |
IgM CSF, all LPs | mg/L | 1 (0.4–3; 15) | 1.05 (0.2–17.8; 26) | 1.2 (0.2–17.8; 17) | 0.9 (0.54–11; 9) | 0.7 (0–36.9; 100) |
IgM CSF, QIgM positives | mg/L | 1.2 (0.42–3; 3) | 9 (5.4–17.8; 5) | 9 (5.4–17.8; 5) | n.a. | n.d. |
IgM serum, all LPs | g/L | 1.68 (0.56–3.75; 16) | 1.6 (0.38–3.68; 29) | 1.45 (0.38–3.68; 20) | 1.7 (0.9–2.2; 9) | 0.96 (0.13–2.85; 99) |
IgM serum, QIgM positives | g/L | 1.51 (0.72–2; 3) | 1.1 (0.64–1.5; 5) | 1.1 (0.64–1.5; 5) | n.a. | n.d. |
QIgA > Qlim(IgA) | Patients | 2/8 (25) | 1/17 (5.9) | 1/12 (8.3) | 0/5 (0) | n.d. |
QIgA > Qlim(IgA) | Samples | 2/15 (13.3) | 1/29 (3.4) | 1/19 (5.3) | 0/10 (0) | 5/88 (6%) |
QIgA, all LPs | – | 1.77 (1.01–5.7; 13) | 2.5 (0.82–9.1; 29) | 2.4 (1–6.6; 19) | 3.3 (0.82–9.1; 10) | 2.1 (0–40.4; 88) |
QIgA, if positive | – | 3.22 (1.73–4.7; 2) | 1 (1–1; 1) | 1 (1–1; 1) | n.a. | 5.1 (3.7–20.2; 5) |
IgAloc, all LPs | mg/L | 0 (0–3.72; 15) | 0 (0–0.08; 29) | 0 (0–0.08; 19) | 0 (0–0; 10) | 0 (0–3.2; 86) |
IgAloc, QIgA positives | mg/L | 2.015 (0.31–3.72; 2) | 0.08 (0.08–0.08; 1) | 0.08 (0.08–0.08; 1) | n.a. | 0.3 (0.03–3.2; 5) |
IgAIF, all LPs | % | 0 (0–0.73; 15) | 0 (0–0.08; 29) | 0 (0–0.08; 19) | 0 (0–0; 10) | 0 (0–7.5; 86) |
IgAIF, QIgA positives | % | 0.425 (0.12–0.73; 2) | 0.08 (0.08–0.08; 1) | 0.08 (0.08–0.08; 1) | n.a. | 5.6 (0.5–7.5; 5) |
IgA CSF, all LPs | mg/L | 2.7 (1.4–16.6; 13) | 4.55 (0.24–19.9; 30) | 3.45 (0.24–17.5; 20) | 8.5 (3.1–19.9; 10) | 4.7 (0–131; 95) |
IgA CSF, QIgA positives | mg/L | 3.79 (2.5–5.08; 2) | 1.1 (1.1–1.1; 1) | 1.1 (1.1–1.1; 1) | n.a. | n.d. |
IgA serum, all LPs | g/L | 1.53 (0.9–2.9; 15) | 1.88 (0.53–3.8; 29) | 1.55 (0.53–3; 19) | 2.6 (1.2–3.8; 10) | 0.96 (0.13–2.85; 99) |
IgA serum, QIgA positives | g/L | 1.26 (1.08–1.45; 2) | 1.1 (1.1–1.1; 1) | 1.1 (1.1–1.1; 1) | n.a. | n.d. |
Immunoglobulin class patterns
Units | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | AQP4-IgG+ NMO [48] | |
---|---|---|---|---|---|---|
Three-class reaction | Samples | 0/16 (0) | 0/32 (0) | 0/21 (0) | 0/11 (0) | 0/87 (0%) |
Two-class reaction | Samples | 2/16 (12.5) | 2/32 (6.3) | 2/21 (9.5) | 0/11 (0) | 5/87 (5.7%) |
IgG + IgM | Samples | 1 | 1 | 1 | 0 | 1/87 (1.1%) |
IgG + IgA | Samples | 1 | 1 | 1 | 0 | 1/87 (1.1%) |
IgM + IgA | Samples | 0 | 0 | 0 | 0 | 3/87 (3.4%) |
One-class reaction | Samples | 5/16 (31.3) | 6/32 (18.8) | 6/21 (28.6) | 0/11 (0) | 13/87 (14.9%) |
Only IgG | Samples | 4 | 2 | 2 | 0 | 5/87 (5.7%) |
Only IgM | Samples | 1 | 4 | 4 | 0 | 7/87 (8%) |
Only IgA | Samples | 0 | 0 | 0 | 0 | 1/87 (1.1%) |
MRZ reaction
Units | MS, according to literature [14] | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | MOG-IgG+ EM [35] | ||
---|---|---|---|---|---|---|---|---|
MRZ reaction (≥2 AIs >1.5) | Patients | 72/100 (72) | 1/2 (50) | 0/10 (0) | 0/7 (0) | 0/3 (0) | 1/42 (2.4) | 0/11 (0) |
Samples | 72/100 (72) | 1/2 (50) | 0/12 (0) | 0/8 (0) | 0/4 (0) | 1/42 (2.4) | 0/11 (0) | |
M and/or R and/or Z >1.5 | Samples | 158/177 (89) | 1/2 (50) | 1/11 (9.1) | 0/8 (0) | 1/3 (33.3) | n.d. | n.d. |
Measles virus AI >1.5 | Samples | 138/177 (78) | 1/2 (50) | 1/10 (10) | 0/8 (0) | 1/4 (25) | 1/42 (2.4) | 0/11 (0) |
Rubella virus AI >1.5 | Samples | 106/177 (60) | 1/2 (50) | 0/9 (0) | 0/8 (0) | 0/4 (0) | 0/42 (0) | 0/11 (0) |
Zoster virus AI >1.5 | Samples | 97/177 (55) | 0/2 (0) | 0/9 (0) | 0/8 (0) | 0/4 (0) | 1/42 (2.4) | 0/11 (0) |
Herpes simplex virus AI >1.5 | Samples | 26/94 (28) | n.d. | 0/4 (0) | 0/4 (0) | 0/1 (0) | n.d. | n.d. |
Epstein–Barr virus AI >1.5 | Samples | n.d. | 0/2 (0) | 0/2 (0) | n.d. | n.d. | n.d. | 0/2 (0) |
Borrelia burgdorferi AI >1.5 | Samples | 0/1 (0) | 0/3 (0) | 0/6 (0) | 0/2 (0) | n.d. | 0/1 (0) | 0/3 (0) |
Toxoplasma gondii AI >1.5 | Samples | n.d. | 0/1 (0) | 0/1 (0) | n.d. | n.d. | n.d. | 0/1 (0) |
TPHA AI >1.5 | Samples | n.d. | 0/1 (0) | 0/1 (0) | n.d. | n.d. | n.d. | 0/1 (0) |
Blood–CSF barrier integrity
Units | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | AQP4-IgG+ NMO [48] | |
---|---|---|---|---|---|---|
QAlb > Qlim(Alb) | Patients | 4/10 (40) | 15/22 (68.2) | 9/15 (60) | 6/7 (85.7) | n.d. |
QAlb > Qlim(Alb) | Samples | 4/17 (23.5) | 30/43 (69.8) | 16/26 (61.5) | 14/17 (82.4) | 75/147 (51%) |
QAlb, all LPs | – | 4.81 (3.01–10.8; 17) | 8.39 (2.1–33.9; 42) | 7.3 (2.1–33.9; 25) | 9 (3.3–20.7; 17) | 7 (2.3–57.1; 137) |
QAlb, QAlb pos. | – | 8.53 (6.3–10.8; 4) | 9.8 (6.4–33.9; 29) | 9 (6.4–33.9; 15) | 10.25 (6.8––20.7; 14) | 11.8 (5.63–57.14; 70) |
Albumin CSF, all LPs | mg/L | 204 (95–517; 17) | 331 (81.2–726; 41) | 255.5 (81.2–599; 24) | 368 (137–726; 17) | 284 (83.6–1890; 139) |
Albumin CSF, QAlb pos. | mg/L | 366 (251–517; 4) | 371.5 (227–726; 28) | 312 (227–599; 14) | 431 (282–726; 14) | 437 (219–1890) |
Albumin serum, all LPs | g/L | 40.6 (29.3–49.5; 17) | 40 (22.6–51.8; 41) | 39.85 (22.6–51.4; 24) | 41.2 (32.7–51.8; 17) | 40.7 (19.7–67.9; 133) |
Albumin serum, QAlb pos. | g/L | 43.15 (37.7–47.9; 4) | 39.5 (22.6–50.9; 27) | 35.55 (22.6–46.8; 14) | 39.9 (32.7–50.9; 13) | 39 (19.7–55.9) |
Combined intrathecal IgG synthesis and disturbed blood–CSF barrier function | ||||||
Patients, at least once |
N (%) | 3/10 (30) | 4/20 (20) | 3/13 (23.1) | 1/7 (14.3) | n.d. |
All LPs |
N (%) | 3/17 (17.6) | 5/43 (11.6) | 4/26 (15.4) | 1/17 (5.9) | 13/74 (17.6%) |
Cellular immune response
Units | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | AQP4-IgG+ NMO [48] | |
---|---|---|---|---|---|---|
Pleocytosis | Samples | 5/13 (38.5) | 16/40 (40) | 6/26 (23.1) | 10/14 (71.4) | 98/194 (50.5) |
WCC, all LPs | Cells/μL | 5 (1–23; 13) | 3 (0–267; 40) | 2 (0–267; 26) | 8.5 (3–24; 14) | 6 (0–380; 182) |
WCC, if elevated | Cells/μL | 11 (6–23; 5) | 14.5 (6–267; 16) | 40 (6–267; 6) | 10.5 (7–24; 10) | 19 (6–380; 98) |
WCC, >40 cells/μL | Samples | 0/13 (0) | 3/36 (8.3) | 3/22 (13.6) | 0/14 (0) | 28/194 (14.4) |
WCC, >40 cells/μL | Cells/μL | n.a. | 69 (55–267; 3) | 69 (55–267; 3) | n.a. | 94 (43–380; 28) |
Albuminocytological dissociation | Samples | 1/8 (12.5) | 13/21 (61.9) | 10/18 (55.6) | 3/3 (100) | 27/75 (33.3) |
Total CSF protein
CSF l-lactate
Units | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | AQP4-IgG+ NMO [48] | |
---|---|---|---|---|---|---|
CSF TP elevated | Patients | 3/9 (33.3) | 14/20 (70) | 8/13 (61.5) | 6/7 (85.7) | n.d. |
CSF TP elevated | Samples | 3/15 (20) | 29/43 (67.4) | 15/26 (57.7) | 14/17 (82.4) | 80/152 (52.6) |
CSF TP, all LPs | mg/L | 375 (187–750; 15) | 550 (168–1930; 43) | 501 (168–1930; 26) | 640 (260–1277; 17) | 473 (198–3620; 147) |
CSF TP, if elevated | mg/L | 724 (532–750; 3) | 622 (470–1930; 29) | 571 (471–1930; 15) | 693 (470–1277; 14) | 780 (45.4–3620; 68) |
CSF TP, >750 mg/L | mg/L | 0/15 (0) | 8/43 (18.6) | 4/26 (15.4) | 4/17 (23.5) | 41/147 (28) |
CSF lactate elevated | Patients | 2/8 (25) | 6/14 (42.9) | 5/11 (45.5) | 1/3 (33.3) | n.d. |
CSF lactate elevated | Samples | 2/9 (22.2) | 7/28 (25) | 6/20 (30) | 1/8 (12.5) | 27/83 (32.5) |
CSF lactate, all LPs | mmol/L | 1.3 (1.1–2.35; 11) | 1.9 (0.8–3.3; 28) | 1.85 (0.8–3.3; 20) | 1.9 (1.36–2.9; 8) | 1.97 (0.87–6.8; 80) |
CSF lactate, if elevated | mmol/L | 2.175 (2–2.35; 2) | 2.5 (2.2–3.3; 7) | 2.4 (2.2–3.3; 6) | 2.9 (2.9–2.9; 1) | 2.9 (2.1–6.8; 27) |
CSF lactate, >3 mmol/L | mmol/L | 0/11 (0) | 1/28 (3.6) | 1/20 (5) | 0/8 (0) | 27/80 (33.8) |
Abnormal vs. normal results
Parameter | Diagnostic groups | Results |
P values |
---|---|---|---|
CSF-restricted OCB, all LPs | Pattern I | 15/17 (88.2) |
P < 0.00004 |
Patterns II + III | 10/37 (27) | ||
Reiber et al. [19] | 262/267 (98) |
P < 0.000001 | |
Patterns II + III | 10/37 (27) | ||
Pattern I | 15/17 (88.2) |
P < 0.0001 | |
Pattern II | 9/25 (36) | ||
Pattern III | 1/12 (8.3) | ||
CSF-restricted OCB, patients | Pattern I | 8/10 (80) |
P < 0.03 |
Patterns II + III | 7/22 (31.8) | ||
Reiber et al. [19] | 262/267 (98) |
P < 0.000001 | |
Patterns II + III | 7/22 (31.8) | ||
CSF-restricted OCB, patients, w/o transient OCBs | Pattern I | 8/10 (80) |
P < 0.006 |
Patterns II + III | 5/22 (22.7) | ||
Reiber et al. [19] | 262/267 (98) |
P < 0.00001 | |
Patterns II + III | 5/22 (22.7) | ||
MRZ reaction (≥2 AIs >1.5), all LPs | Jarius et al. [23] | 397/546 (69) |
P < 0.000001 |
Patterns II + III | 0/12 (0) | ||
M and/or R and/or Z >1.5, all LPs | Reiber et al. [19] | 158/177 (89) |
P < 0.000001 |
Patterns II + III | 0/12 (0) | ||
QIgG > Qlim(lgG), all LPs | Pattern I | 7/17 (41.2) |
P < 0.03 |
Patterns II + III | 5/41 (12.2) | ||
QAlb > Qlim(Alb), all LPs | Pattern I | 4/17 (23.5) |
P < 0.002 |
Patterns II + III | 30/43 (69.8) | ||
Pattern I | 4/17 (23.5) |
P = 0.002 | |
Pattern II | 16/26 (61.5) | ||
Pattern III | 14/17 (82.4) | ||
QAlb, all LPs | Pattern I | 4.81 (3.01–10.8; 17) |
P < 0.005 |
Patterns II + III | 8.39 (2.1–33.9; 42) | ||
Albumin CSF, all LPs | Pattern I | 204 (95–517; 17) |
P < 0.009 |
Patterns II + III | 331 (81.2–726; 41) | ||
Total CSF protein elevated, all LPs | Pattern I | 3/15 (20) |
P < 0.003 |
Patterns II + III | 29/43 (67.4) | ||
Total CSF protein, all LPs | Pattern I | 375 (187–750; 15) |
P < 0.007 |
Patterns II + III | 550 (168–1930; 43) | ||
Albuminocytological dissociation, all LPs | Pattern I | 1/8 (12.5) |
P < 0.04 |
Patterns II + III | 13/21 (61.9) |